Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: The VESIcare open-label trial (VOLT)
Authors:
- Alan D. GarelyAGAlan D. Garely
- Joel M. KaufmanJKJoel M. Kaufman
- Peter K. SandPSPeter K. Sand
- Neila SmithNSNeila Smith
- Masakazu AndohMAMasakazu Andoh
- 1 November 2006
- journal article
- clinical trial
- Published by Elsevier in Clinical Therapeutics
- Vol. 28 (11) , 1935-1946
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- The Validation of the Patient Perception of Bladder Condition (PPBC): A Single-Item Global Measure for Patients with Overactive BladderEuropean Urology, 2006
- The patient's perspective: Redefining end pointsUrology, 2004
- RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF THE ONCE DAILY ANTIMUSCARINIC AGENT SOLIFENACIN SUCCINATE IN PATIENTS WITH OVERACTIVE BLADDERJournal of Urology, 2004
- The Impact of Urinary Urgency and Frequency on Health-Related Quality of Life in Overactive Bladder: Results from a National Community SurveyValue in Health, 2004
- Randomized, double‐blind placebo‐ and tolterodine‐controlled trial of the once‐daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladderBJU International, 2004
- Prevalence and burden of overactive bladder in the United StatesWorld Journal of Urology, 2003
- Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: The OAB-qQuality of Life Research, 2002
- The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence SocietyNeurourology and Urodynamics, 2002
- Treatment of Overactive Bladder with Once-daily Extended-release Tolterodine or Oxybutynin: The Antimuscarinic Clinical Effectiveness Trial (ACET)Current Medical Research and Opinion, 2002
- The patient with an overactive bladder—Symptoms and quality-of-life issuesUrology, 1997